Last Thursday, our COO and co-founder @eric_k_morgen , MD spoke at the Massachusetts State House, advocating for a fundamental shift in how we approach age-related disease. 80% of adults over 65 live with at least one chronic condition, driving over $500 billion in annual healthcare costs. But how do we translate advances in the science of longevity into treatments that improve quality of life for older adults living with multiple chronic diseases? At BioAge, we're answering this question by analyzing the world's most comprehensive human aging datasets—50+ million molecular data points spanning over 50 years—to identify therapeutic targets that address root causes of metabolic disease. Our advancing clinical programs, along with multiple pharma collaborations, demonstrate how human aging biology can inform drug discovery. Massachusetts —along with the other great states investing in innovation — has an opportunity to take the lead in aging biology research. State-level life sciences funding initiatives could accelerate the translation of aging science into therapeutics that extend healthy lifespan and reduce the burden of chronic disease. Grateful to the @aginginit and the MA Joint Committee on Aging and Independence for organizing this briefing and creating the space for science, policy, and patient impact to converge.